导管起始血透患者血管通路选择的临床与经济效应
该研究纳入479例以中心静脉导管起始血透的患者,比较后续建立AVF、AVG或无动静脉通路(CVC组)的临床与经济影响。结果显示AVF组手术操作更频繁且年费用更高,AVG组费用较低,CVC组总体费用最高,主要归因于导管相关菌血症住院。
要点
- 以CVC起始血透后建立AVF者,年手术操作次数高于AVG者。
- AVF组年通路相关总费用中位数高于AVG组。
- CVC组年通路相关总费用最高,主因导管相关菌血症住院。
核心结论
- 以CVC起始血透的患者中,初始建立AVF者年通路相关操作与并发症费用高于初始建立AVG者。
研究设计与样本
- 在大型医疗中心(2004-2012年)识别479例以CVC起始血透的患者,其中AVF组295例、AVG组105例、无动静脉通路CVC组71例。
主要发现
- AVF组年手术通路操作次数为1.01(95%CI 0.95-1.08),AVG组为0.62(95%CI 0.55-0.70),P<0.001。
- AVF组年手术通路操作费用中位数为4857美元(IQR 2523-8835),AVG组为2819美元(IQR 1411-4274),P<0.001。
- 控制年龄、性别、种族和糖尿病后,AVF组年通路相关总费用中位数为10642美元(IQR 5406-19878),AVG组为6810美元(IQR 3718-13651),P=0.001。
- CVC组年通路相关总费用中位数最高,为28709美元(IQR 11793-66917),P<0.001,主要归因于导管相关菌血症住院频率高。
临床怎么用
- 以CVC起始血透的患者在选择后续动静脉通路时,需权衡AVF与AVG的操作频率及费用差异。
- 应重视CVC组导管相关菌血症导致的高住院费用,加强导管管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients in the United States frequently initiate hemodialysis with a central venous catheter (CVC) and subsequently undergo placement of a new arteriovenous fistula (AVF) or arteriovenous graft (AVG). Little is known about the clinical and economic effects of initial vascular access choice. We identified 479 patients starting hemodialysis with a CVC at a large medical center (during 2004-2012) who subsequently had an AVF (n=295) or AVG (n=105) placed or no arteriovenous access (CVC group, n=71). Compared with patients receiving an AVG, those receiving an AVF had more frequent surgical access procedures per year (1.01 [95% confidence interval, 0.95 to 1.08] versus 0.62 [95% confidence interval, 0.55 to 0.70]; P<0.001) but a similar frequency of percutaneous access procedures per year. Patients receiving an AVF had a higher median annual cost (interquartile range) of surgical access procedures than those receiving an AVG ($4857 [$2523-$8835] versus $2819 [$1411-$4274]; P<0.001), whereas the annual cost of percutaneous access procedures was similar in both groups. The AVF group had a higher median overall annual access-related cost than the AVG group ($10,642 [$5406-$19,878] versus $6810 [$3718-$13,651]; P=0.001) after controlling for patient age, sex, race, and diabetes. The CVC group had the highest median annual overall access-related cost ($28,709 [$11,793-$66,917]; P<0.001), largely attributable to the high frequency of hospitalizations due to catheter-related bacteremia. In conclusion, among patients initiating hemodialysis with a CVC, the annual cost of access-related procedures and complications is higher in patients who initially receive an AVF versus an AVG.
引用
- Al-Balas A, Lee T, Young CJ, et al. The Clinical and Economic Effect of Vascular Access Selection in Patients Initiating Hemodialysis with a Catheter. J Am Soc Nephrol. 2017. PMID: 28710090. doi:10.1681/ASN.2016060707
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。